S&P 500   5,083.71 (+0.28%)
DOW   38,923.47 (-0.07%)
QQQ   438.28 (+0.69%)
AAPL   181.44 (+0.01%)
MSFT   408.47 (+0.18%)
META   489.80 (+1.19%)
GOOGL   137.40 (+0.75%)
AMZN   174.88 (+0.99%)
TSLA   201.81 (-0.11%)
NVDA   795.89 (+2.48%)
NIO   5.66 (+4.24%)
AMD   187.40 (+6.15%)
BABA   74.33 (-0.35%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.61 (-0.11%)
CGC   3.34 (-0.60%)
GE   155.84 (+0.15%)
DIS   111.70 (+0.81%)
AMC   4.42 (-11.42%)
PFE   26.97 (-0.26%)
PYPL   60.86 (+1.01%)
XOM   104.28 (-0.04%)
S&P 500   5,083.71 (+0.28%)
DOW   38,923.47 (-0.07%)
QQQ   438.28 (+0.69%)
AAPL   181.44 (+0.01%)
MSFT   408.47 (+0.18%)
META   489.80 (+1.19%)
GOOGL   137.40 (+0.75%)
AMZN   174.88 (+0.99%)
TSLA   201.81 (-0.11%)
NVDA   795.89 (+2.48%)
NIO   5.66 (+4.24%)
AMD   187.40 (+6.15%)
BABA   74.33 (-0.35%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.61 (-0.11%)
CGC   3.34 (-0.60%)
GE   155.84 (+0.15%)
DIS   111.70 (+0.81%)
AMC   4.42 (-11.42%)
PFE   26.97 (-0.26%)
PYPL   60.86 (+1.01%)
XOM   104.28 (-0.04%)
S&P 500   5,083.71 (+0.28%)
DOW   38,923.47 (-0.07%)
QQQ   438.28 (+0.69%)
AAPL   181.44 (+0.01%)
MSFT   408.47 (+0.18%)
META   489.80 (+1.19%)
GOOGL   137.40 (+0.75%)
AMZN   174.88 (+0.99%)
TSLA   201.81 (-0.11%)
NVDA   795.89 (+2.48%)
NIO   5.66 (+4.24%)
AMD   187.40 (+6.15%)
BABA   74.33 (-0.35%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.61 (-0.11%)
CGC   3.34 (-0.60%)
GE   155.84 (+0.15%)
DIS   111.70 (+0.81%)
AMC   4.42 (-11.42%)
PFE   26.97 (-0.26%)
PYPL   60.86 (+1.01%)
XOM   104.28 (-0.04%)
S&P 500   5,083.71 (+0.28%)
DOW   38,923.47 (-0.07%)
QQQ   438.28 (+0.69%)
AAPL   181.44 (+0.01%)
MSFT   408.47 (+0.18%)
META   489.80 (+1.19%)
GOOGL   137.40 (+0.75%)
AMZN   174.88 (+0.99%)
TSLA   201.81 (-0.11%)
NVDA   795.89 (+2.48%)
NIO   5.66 (+4.24%)
AMD   187.40 (+6.15%)
BABA   74.33 (-0.35%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.61 (-0.11%)
CGC   3.34 (-0.60%)
GE   155.84 (+0.15%)
DIS   111.70 (+0.81%)
AMC   4.42 (-11.42%)
PFE   26.97 (-0.26%)
PYPL   60.86 (+1.01%)
XOM   104.28 (-0.04%)

Trellus Health (TRLS) Competitors

GBX 3.05
-0.20 (-6.15%)
(As of 12:16 PM ET)

TRLS vs. IQAI, FDBK, INHC, COG, OCTP, IMM, GENF, IXI, VAL, and CNSL

Should you be buying Trellus Health stock or one of its competitors? The main competitors of Trellus Health include IQ-AI (IQAI), Feedback (FDBK), Induction Healthcare Group (INHC), Cambridge Cognition (COG), Oxford Cannabinoid Technologies (OCTP), ImmuPharma (IMM), Genflow Biosciences (GENF), IXICO (IXI), ValiRx (VAL), and Cambridge Nutritional Sciences (CNSL). These companies are all part of the "medical" sector.

Trellus Health vs.

IQ-AI (LON:IQAI) and Trellus Health (LON:TRLS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.

IQ-AI has a beta of 2.96, suggesting that its share price is 196% more volatile than the S&P 500. Comparatively, Trellus Health has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

2.8% of IQ-AI shares are held by institutional investors. Comparatively, 13.5% of Trellus Health shares are held by institutional investors. 34.0% of IQ-AI shares are held by company insiders. Comparatively, 57.5% of Trellus Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Trellus Health has a net margin of 0.00% compared to Trellus Health's net margin of -85.53%. IQ-AI's return on equity of -29.34% beat Trellus Health's return on equity.

Company Net Margins Return on Equity Return on Assets
IQ-AI-85.53% -77.81% -24.00%
Trellus Health N/A -29.34%-17.82%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IQ-AI
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Trellus Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

IQ-AI received 6 more outperform votes than Trellus Health when rated by MarketBeat users.

CompanyUnderperformOutperform
IQ-AIOutperform Votes
6
66.67%
Underperform Votes
3
33.33%
Trellus HealthN/AN/A

In the previous week, IQ-AI had 2 more articles in the media than Trellus Health. MarketBeat recorded 2 mentions for IQ-AI and 0 mentions for Trellus Health. Trellus Health's average media sentiment score of 0.92 beat IQ-AI's score of 0.00 indicating that IQ-AI is being referred to more favorably in the media.

Company Overall Sentiment
IQ-AI Positive
Trellus Health Neutral

IQ-AI has higher revenue and earnings than Trellus Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQ-AI£538.19K6.17N/AN/AN/A
Trellus Health£35K140.74-£7.54M£0.01305.00

Summary

Trellus Health beats IQ-AI on 7 of the 12 factors compared between the two stocks.


Get Trellus Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRLS vs. The Competition

MetricTrellus HealthHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£4.93M£229.16M£4.97B£1.34B
Dividend YieldN/A6.11%2.87%12.11%
P/E Ratio305.00581.39192.621,690.84
Price / Sales140.74924.883,024.89407,739.47
Price / Cash0.7638.9394.4832.63
Price / Book0.227.224.482.50
Net Income-£7.54M-£5.35M£112.73M£182.31M
7 Day Performance-18.67%0.59%5.35%-0.19%
1 Month Performance-32.22%4.22%10.50%-0.42%
1 Year Performance-56.43%-9.59%13.09%5.89%

Trellus Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IQAI
IQ-AI
0 of 5 stars
GBX 1.73
-1.1%
N/A-42.0%£3.40M£538,190.00-13.676
FDBK
Feedback
0 of 5 stars
GBX 70
flat
N/A-59.5%£9.33M£1.02M-269.2324News Coverage
INHC
Induction Healthcare Group
0 of 5 stars
GBX 16
flat
N/A-20.6%£14.78M£11.82M-106.6783
COG
Cambridge Cognition
0 of 5 stars
GBX 51.50
flat
N/A-55.0%£18.00M£12.77M-468.1880
OCTP
Oxford Cannabinoid Technologies
0 of 5 stars
GBX 0.44
flat
N/A-43.2%£4.80MN/A-53.107Gap Up
IMM
ImmuPharma
0 of 5 stars
GBX 1.09
-0.9%
N/A-51.1%£4.54M£94,819.00-109.0013Gap Down
GENF
Genflow Biosciences
0 of 5 stars
GBX 1.50
-3.2%
N/A-38.9%£4.39MN/A-256.005Gap Down
IXI
IXICO
0 of 5 stars
GBX 8.75
flat
N/A-66.0%£4.23M£6.67M-437.5089News Coverage
VAL
ValiRx
0 of 5 stars
GBX 4.25
flat
N/A-63.0%£5.63MN/A-141.678News Coverage
Negative News
CNSL
Cambridge Nutritional Sciences
0 of 5 stars
GBX 2.52
-5.0%
N/AN/A£5.99M£9.05M-251.8091

Related Companies and Tools

This page (LON:TRLS) was last updated on 2/29/2024 by MarketBeat.com Staff